We designed a prospective study to assess the time course and evolution of hepatitis C virus (HCV) infection in 152 patients who underwent a liver transplantation (LT) in our institution. Forty-four recipients (29%) were infected by HCV after transplantation: 40 who developed recurrent infection after LT and four who acquired infection during or after LT. No differences were found in survival actuarial rates at 1, 2, and 4 years after transplantation for patients infected by HCV vs. noninfected ones. Graft hepatitis occurred in 66% of HCV-infected recipients: 18 developed chronic active hepatitis (10 of them with intense fibrosis) and 2 developed cirrhosis during the follow-up. Infection by the HCV-1b genotype was found in 79% of the infected recipients and in 100% of those in whom histologic evolution was worst. Fourteen grafts were lost in 44 HCV-infected recipients, in comparison with 12 in 108 HCV-negative patients (P = .007), mostly because of chronic rejection. HCV infection did not affect life expectancy in the midterm follow-up for LT patients. However, it was often associated with the occurrence of early and severe graft hepatitis and with a higher incidence of graft loss due to chronic rejection.

BACKGROUND We wanted to investigate the influence of viral genotype on the severity of liver injury and response to interferon and whether the level of viremia differs in accordance with genotype, severity of liver disease, and response to interferon in patients with hepatitis C virus (HCV) infection. METHODS We studied 118 patients with HCV-related liver disease. HCV genotypes were determined with a line probe assay, and serum HCV RNA levels with a competitive reverse transcription polymerase chain reaction assay. RESULTS HCV type 1b was the most prevalent genotype (88%). It was present in 100% of cirrhotic patients, with or without hepatocellular carcinoma (HCC), but only in 78% of patients with chronic hepatitis (P < 0.001). The response to interferon was better in patients infected with non-1b HCV genotypes (P = 0.002). In a multivariate analysis non-1b HCV genotypes and a low hepatic fibrosis correlated with a favorable response to interferon. Among patients with chronic hepatitis those infected with HCV type 1b were older (P < 0.001), and age was the only independent factor associated with HCV type 1b. Viremia levels differed neither between genotypes nor in response to interferon and was significantly lower in patients with cirrhosis and HCC. CONCLUSIONS HCV 1b was associated with more severe liver disease and a worse response to interferon therapy. Non-1b genotypes and a lower liver fibrosis were the only independent predictors of a favorable response to interferon. Levels of HCV viremia differed neither among different genotypes nor in response to interferon and decreased with advanced liver disease.

BACKGROUND:Recent development of an assay based on the hybridization of the amplification product obtained by polymerase chain reaction (PCR) of the RNA of hepatitis C virus (HCV) with specific probes for each viral genotype ("reverse-hybridization"), has permitted to have a rapid, simple and reproductible technique to identify the different genotypes of HCV. The identification of HCV genotypes seems to be important given their different pathogenic capacity and response to interferon therapy.METHODS:We prospectively studied 221 patients with HCV infection defined by the detection of viral RNA in serum by "nested-PCR". HCV genotype was determined by "reverse-hybridization" using specific oligonucleotide-probes for each genotype corresponding to the 5, UTR.RESULTS:HCV 1b genotype was predominant in 221 patients studied (180/221, 81%), followed by 1a (10%) and by 3 and 4 (4% respectively). Two patients presented mixed infection (1a/1b). No case of infection by genotypes 2 and 5 was found. The predominance of 1b genotype was more evident in adults than in children (83 vs 62%) (p < 0.05).CONCLUSIONS:HCV 1b is the predominant genotype among our patients with hepatic disease induced by HCV. The reverse-hybridization assay is a simple and rapid technique that permit the identification of the most important genotypes of hepatitis C virus.